Results 21 to 30 of about 23,408 (219)
Molecules, 2021 The multi-target-directed ligands (MTDLs) strategy is encouraged for the development of novel modulators targeting multiple pathways in the neurodegenerative cascade typical for Alzheimer’s disease (AD). Based on the structure of an in-house irreversible
Tjaša Mazej +4 more
doaj +1 more source
Computation-based experimentation: Identification of piperazine containing antidepressants
Pakistan Journal of Pharmaceutical Sciences, 2021 Depression, a common mental disorder, is one of the major contributors to the overall global burden with more than 264 million individuals affected worldwide. Monoamine oxidase inhibitors (MAOIs) have well-known efficacy for treating depression and other
Saman Usmani +6 more
doaj +1 more source
monoamine oxidase inhibitors revisited [PDF]
Canadian Journal of Anaesthesia, 1989 Until recently, traditional teaching has been to discontinue MAOI therapy two to three weeks before surgery. The literature and texts relating to the concurrent use of MAOI’s with anaesthesia are confusing, outdated and often contradictory. Significant adverse drug reactions can and have occurred in a minority of patients receiving MAOI’s.
D G, Wells, A R, Bjorksten
openaire +2 more sources
Frontiers in Pharmacology, 2021 Mucosal epithelial cell integrity is an important component of innate immunity and it protects the host from an environment rich in microorganisms. Virulence factors from Gram-negative bacteria [e.g.
Edward E. Putnins +2 more
doaj +1 more source
Computer-aided approach for the identification of lead molecules as the inhibitors of cholinesterase’s and monoamine oxidases: Novel target for the treatment of Alzheimer disease [PDF]
Journal of the Serbian Chemical SocietyMolecular docking is a promising and reliable technology for the purpose of discovering lead compounds via virtual screening. In addition to allowing for the testing of a large number of compounds, it also allows for the determination of how the selected
Ejaz Syeda Abida +4 more
doaj +1 more source
Molecules, 2022 Monoamine oxidases (MAOs) are attractive targets in drug design. The inhibition of one of the isoforms (A or B) is responsible for modulating the levels of different neurotransmitters in the central nervous system, as well as the production of reactive ...
Marco Mellado +9 more
doaj +1 more source
Coumarin analogue 3-methyl-7H-furo[3,2-g] chromen-7-one as a possible antiparkinsonian agent
Biomédica: revista del Instituto Nacional de Salud, 2019 Introduction: Parkinson’s disease is the second most common neurodegenerative disease. Monoamine oxidase B inhibitors are used in the treatment of this disease concomitantly with levodopa or as monotherapy.
María del Pilar Olaya +4 more
doaj +1 more source
PYRAZOLINES WITH ANTICONVULSANT AND MAO INHIBITORY ACTIVITIES [PDF]
Al-Azhar Journal of Pharmaceutical Sciences, 2014 2-Pyrazolines (4,5-dihydro-1H-pyrazole) are an important class of five-membered heterocyclic compounds and were found to be vital building block in medicinal chemistry and led to the discovery of a number of bioactive derivatives.
Mohamed Aboul-Enein
doaj +1 more source
Design and Synthesis of Novel and Potent Monoamine Oxidase Inhibitors
CHIMIA, 1995 Reversible and selective monoamine oxidase-A inhibitors (RIMA's) like moclobemide (Aurorix®) have rehabilitated the use of MAO inhibitors as drugs of choice in depression.
Quirico Branca +4 more
doaj +2 more sources
Structure-Activity Relationship Analysis of 3-Phenylcoumarin-Based Monoamine Oxidase B Inhibitors
Frontiers in Chemistry, 2018 Monoamine oxidase B (MAO-B) catalyzes deamination of monoamines such as neurotransmitters dopamine and norepinephrine. Accordingly, small-molecule MAO-B inhibitors potentially alleviate the symptoms of dopamine-linked neuropathologies such as depression ...
Sanna Rauhamäki +20 more
doaj +1 more source